The University of Chicago Header Logo

Connection

Walter M. Stadler to Angiogenesis Inhibitors

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Angiogenesis Inhibitors.
Walter M. Stadler
Connection Strength
3.798
Angiogenesis Inhibitors
  1. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.476
  2. Maturing of renal cancer therapeutics. J Clin Oncol. 2014 Mar 10; 32(8):722-4.
    View in: PubMed
    Score: 0.400
  3. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis. Technol Cancer Res Treat. 2013 Feb; 12(1):71-8.
    View in: PubMed
    Score: 0.360
  4. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol. 2009 Apr 01; 27(10):1557-63.
    View in: PubMed
    Score: 0.284
  5. Angiogenesis inhibition in non-clear cell renal cancer. Clin Adv Hematol Oncol. 2008 Jul; 6(7):507-9.
    View in: PubMed
    Score: 0.271
  6. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
    View in: PubMed
    Score: 0.219
  7. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22.
    View in: PubMed
    Score: 0.215
  8. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
    View in: PubMed
    Score: 0.204
  9. Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S41-7.
    View in: PubMed
    Score: 0.191
  10. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med. 2002 Nov; 113(7):603-6.
    View in: PubMed
    Score: 0.183
  11. Angiogenesis inhibitors. Curr Oncol Rep. 2000 Jan; 2(1):11-6.
    View in: PubMed
    Score: 0.150
  12. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999 Aug; 17(8):2541-5.
    View in: PubMed
    Score: 0.146
  13. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.
    View in: PubMed
    Score: 0.098
  14. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6.
    View in: PubMed
    Score: 0.078
  15. Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4.
    View in: PubMed
    Score: 0.072
  16. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008 Aug 01; 26(22):3743-8.
    View in: PubMed
    Score: 0.068
  17. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
    View in: PubMed
    Score: 0.067
  18. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.
    View in: PubMed
    Score: 0.062
  19. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 01; 104(11):2323-33.
    View in: PubMed
    Score: 0.057
  20. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.051
  21. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
    View in: PubMed
    Score: 0.045
  22. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec; 20(6):575-580.
    View in: PubMed
    Score: 0.045
  23. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
    View in: PubMed
    Score: 0.041
  24. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.